March 03, 2015 4:38 AM ET

Biotechnology

Company Overview of Edimer Pharmaceuticals Inc.

Executive Profile

Neil Kirby Ph.D.

Chief Executive Officer, President and Director, Edimer Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 3 different industries.

See Board Relationships
53--

Background

Dr. Neil Kirby Ph.D. serves as the President and Chief Executive Officer at Edimer Pharmaceuticals Inc. Dr. Kirby has been an Independent Consultant to the pharmaceutical industry, advising both public and private companies on regulatory strategy, M&A activities and organizational design and development. He has been Senior Vice President of Strategic Product Development of Shire Human Genetic Therapies Inc. since November 12, 2004 and was section 16b officer. Dr. Kirby ...

Corporate Headquarters

1 Broadway
Cambridge, Massachusetts 02142

United States

Phone: 617-758-4300
Fax: 866-334-4240

Board Members Memberships

Chief Executive Officer, President and Director

Education

PhD
University Of London
Bachelor's Degree
University Of London

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Edimer Pharmaceuticals Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.